Faruqi and Faruqui, LLP Logo
Share this page

NewLink Genetics Corporation (NLNK)



Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Investing In NewLink Genetics Corporation (NLNK) To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at NewLink Genetics Corporation (“NewLink” or the “Company”) (NASDAQGM:NLNK).

The investigation focuses on whether the Company and its executives violated federal securities laws by failing to disclose that NewLink’s immunotherapy drug, indoximod, was not showing a meaningful benefit in its Phase 2 trial for patients with advanced melanoma.

Since the results of the Phase 2 trial were announced on April 4, 2017, the stock has dropped more than 10% on unusually heavy volume.

Take Action

If you invested in NewLink stock or options between October 25, 2016 and April 3, 2017 and would like to discuss your legal rights, please fill out the form below.  You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com.  Faruqi & Faruqi, LLP also encourages anyone with information regarding NewLink’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Request Information

Please tell us about yourself by completing the form and we will provide you with additional
information on how to join the Class Action at no cost to you.

  • Case:
    NewLink Genetics Corporation (NLNK)

* The submission of this form does not create an attorney-client relationship.

Contact Counsel

Richard W. Gonnello
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330


Case Details


  • 04/04/2017

Send Information

If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.